Aminobenzoic acids and derivatives

Apexbio Technology LLC Deferoxamine mesylate 138-14-7 500mg

Deferoxamine mesylate (CAS 138-14-7) is an iron-specific chelating agent used primarily to manage acute iron poisoning It binds iron ions to form a water-soluble complex ferrioxamine thus preventing iron from participating in harmful oxidative reactions and facilitating renal excretion In rat mammary adenocarcinoma models deferoxamine mesylate treatment particularly combined with low-iron diet reduces tumor growth Additionally preoperative administration attenuates oxidative stress markers and pancreatic tissue damage by inducing HIF-1 expression in rat liver transplantation studies highlighting its utility in anticancer and cytoprotective research

TARGETMOL CHEMICALS INC Deferoxamine Mesylate 1G

Also available in 1 mL, 50 mg, 100 mg, 500 mg and bulk. Please contact Fisher for quotes. Deferoxamine Mesylate (DFOM) is an iron chelator and ferroptosis inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1alpha levels and induces apoptosis. Purity 99.8%

Medchemexpress LLC PBT434 methanesulfonate | 2387898-69-1 | 99.9% | 1 MG

PBT434 mesylate (PBT434 methanesulfonate, ATH434) is a brain-penetrant, orally active small molecule inhibitor of α-synuclein aggregation with iron-chelating activity, supplied for research use in studies of synucleinopathies and neurodegeneration.

• Inhibits α-synuclein aggregation and reduces iron-mediated aggregation.
• Acts as an iron chelator and modulates iron trafficking.
• Brain-penetrant and orally active, suitable for in vivo studies.
• High purity appropriate for biochemical and cellular assays.
• Solid, white to off-white appearance; store sealed at 4°C.

Medchemexpress LLC PBT434 mesylate | 2387898-69-1 | 25 MG

PBT434 mesylate is the methanesulfonate salt of PBT434, a brain-penetrant, orally active small molecule inhibitor of α-synuclein aggregation used in preclinical Parkinson's disease research.

• Acts as an iron chelator and modulates transcellular iron trafficking.
• Inhibits iron-mediated redox activity and α-synuclein aggregation.
• Orally active and crosses the blood-brain barrier.
• Supplied as a mesylate salt, solid, white to off-white.
• High purity suitable for research (99.9%).

Medchemexpress LLC PBT434 mesylate | 2387898-69-1 | 99.9% | 50 MG

PBT434 mesylate is the methanesulfonate salt of a small-molecule inhibitor of α-synuclein aggregation that demonstrates oral activity and crosses the blood-brain barrier, supplied for preclinical research. It also exhibits iron-modulating properties and is provided as a high-purity solid with defined storage conditions.

• High purity: 99.9%.
• Molecular weight 398.26 g·mol⁻1.
• Chemical formula C13H17Cl2N3O5S.
• Available in small pack sizes including 50 MG.
• Store sealed at 4°C; in solvent keep at -80°C up to 6 months, or -20°C up to 1 month.
• Intended for preclinical studies of protein aggregation and iron modulation; follow appropriate safety guidance.

Selleck Chemical LLC Deferoxamine mesylate

Deferoxamine mesylate is the mesylate salt of Deferoxamine which forms iron complexes and is used as a chelating agent Deferoxamine is a ferroptosis inhibitor that stabilizes HIF-1 expression and improves HIF-1 transactivity in hypoxic and hyperglycemic states in vitro Deferoxamine decreases beta-amyloid (A ) deposition and induces autophagy Please do not prepare stock solutions with normal saline or PBS as precipitation may occur

Selleck Chemical LLC Deferoxamine mesylate

Deferoxamine mesylate is the mesylate salt of Deferoxamine which forms iron complexes and is used as a chelating agent Deferoxamine is a ferroptosis inhibitor that stabilizes HIF-1 expression and improves HIF-1 transactivity in hypoxic and hyperglycemic states in vitro Deferoxamine decreases beta-amyloid (A ) deposition and induces autophagy Please do not prepare stock solutions with normal saline or PBS as precipitation may occur

Medchemexpress LLC PBT434 methanesulfonate | 2387898-69-1 | 99.9% | 10 MG

PBT434 mesylate is the methanesulfonate salt of PBT434, an orally active, blood-brain barrier-penetrant small molecule that inhibits α-synuclein aggregation and modulates iron-mediated redox activity for preclinical neurodegeneration research.

• Orally active α-synuclein aggregation inhibitor.
• Crosses the blood-brain barrier.
• High purity suitable for research use.
• Soluble in DMSO at approximately 100 mg/mL; ultrasonic agitation recommended.
• Store solid at 4°C sealed; stock solutions tolerate -80°C for long-term storage.